Skip to main content
Caplight Logo









ArteraAI

ArteraAI

Private
Los Altos, CaliforniaHealthcare & Life Scienceshttps://artera.ai/

Last Round

VC Round

Feb 1, 2024

Company Overview

ArteraAI is a precision medicine company that develops AI-enabled predictive and prognostic cancer tests to personalize therapy for cancer patients.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Medical AI, Biotechnology, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

precision medicinemultimodal AIMMAIdigital pathologycancer diagnosticsoncology AIclinical decision supportrisk stratificationAI pathologydiagnostic assaybiomarker discoveryprostate cancer testbreast cancer testAI diagnosticscomputational pathology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ArteraAI Comparables

Compare ArteraAI with similar companies based on industry and business-model similarity.

ArteraAI comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Valar Labs
79%
Avenda Health
74%
Nanostics Inc.
73%

ArteraAI Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundFeb 1, 2024
VC RoundMar 21, 2023

Key People

Founding team and executive leadership

Andre Esteva

Co-Founder And CEO

Founding Team

Nathan Silberman

Chief Technology Officer

Executive Team

ArteraAI Investors

Notable investors and investment history

ArteraAI investors
InvestorRounds
Breyer CapitalVC Round
TIME VenturesVC Round
Koch-ventures.comVC Round
EDBIVC Round
A&E InvestmentsVC Round
Walden CatalystVC Round
Koch Disruptive TechnologiesVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 9, 2025

    Launched ArteraAI Prostate Test (Post-RP) for biochemical recurrence.

  • Nov 24, 2025

    New data demonstrates prognostic and predictive utility for breast cancer.

ArteraAI Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ArteraAI Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ArteraAI's valuation, stock price, and market status.

Firmographic Details

HeadquartersLos Altos, California
Employee Range150
Year Founded2021
Last FundingFeb 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?